Navigation Links
CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011
Date:10/27/2011

expense was $91,000 for the first nine months of 2011 compared to $2.5 million for the first nine months of 2010.  Other expense of $3.3 million in the third quarter of 2010 consisted primarily of a $3.6 million charge related to impairment of the investment in Medafor common stock.  Other expense of $2.5 million in the first nine months of 2010 consisted primarily of the $3.6 million charge related to the impairment of the investment in Medafor common stock, partially offset by a $1.3 million gain on valuation of the derivative related to the investment in Medafor common stock.

As of September 30, 2011, the Company had $26.4 million in cash, cash equivalents, and restricted securities, compared to $40.8 million at December 31, 2010.  The decrease in cash, cash equivalents, and restricted securities is largely a result of the $21.7 million paid for the acquisition of Cardiogenesis in the second quarter of 2011 and $3.5 million paid for the purchase of Senior A Preferred stock of ValveXchange in early July 2011, partially offset by operating cash flows.  Of this $26.4 million in cash, cash equivalents, and restricted securities, $1.4 million was received from the U.S. Department of Defense as advance funding for the development of BioFoam protein hydrogel technology, and $5.3 million was designated as restricted securities primarily due to a financial covenant requirement under the Company's credit agreement.  The Company's net cash flows provided by operations were $13.7 million for the first nine months of 2011 and $13.8 million for the first nine months of 2010.  

2011 Financial Guidance The Company expects total revenues for the full year of 2011 to be slightly below the lower end of its range of between $122.0 million and $125.0 million, which include revenues of approximately $500,000 related to the use of funds received from the U.S. Department of Defense in connection with the development of BioFoam.  The C
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic
2. CryoLife Receives FDA Approval to Begin U.S. Clinical Trial for BioFoam(R)
3. CryoLife Reports Record Quarterly Revenues of $28.2 Million
4. CryoLife to Present at Upcoming Investor Conferences in New York
5. CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference
6. CryoLife Provides Initial 2010 Financial Guidance
7. CryoLife Enters into Worldwide Distribution and Manufacturing Agreements with Starch Medical for Novel Hemostatic Agent
8. CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive
9. CryoLife Announces Release Date and Teleconference Call Details for 2010 Third Quarter Financial Results
10. CryoLife Begins Distribution of Blood-Clotting Agent PerClot® in Europe
11. CryoLife to Present at Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Colo. , Jan. 22, 2015  BiOptix is pleased ... as Vice President of Chemistry and Biochemistry. Scott joins ... Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course of ... development. "Scott is a nationally recognized thought ...
(Date:1/22/2015)... , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... focus on Omega-3 therapies for cardiovascular disease and overall health ... Company,s accomplishments in 2014 and its outlook for 2015 from ... Fellow Shareholders, We would like to take this ...
(Date:1/22/2015)...  Profil Institute for Clinical Research, Inc., a clinical research ... a new textbook,  Translational Research Methods for Diabetes, Obesity ... global scientific publisher. The textbook is the ... in early phase clinical studies of new drugs for ...
Breaking Medicine Technology:BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3
... (Nasdaq: OPTR ) today announced that the Company ... June 8, 2011 at 11:00 a.m. Eastern Time at The ... http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) A live audio webcast of this ... Company,s website at www.optimerpharma.com . Replays of this presentation ...
... Va., June 1, 2011 Mirixa Corporation is pleased ... a licensing agreement for MirixaEdge(SM), a clinical application that ... Medication Therapy Management (MTM). Family Physicians Group ... One Source Pharmacy and selected it as FPG,s preferred ...
Cached Medicine Technology:Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference 2MirixaEdge(SM) to be Licensed by One Source Pharmacy, LLC 2MirixaEdge(SM) to be Licensed by One Source Pharmacy, LLC 3
(Date:1/22/2015)... 22, 2015 Deer Path of Huntley ... Valentine’s Day Happy Hour from 3 p.m. to 4 p.m. on ... Parkway in Huntley, Illinois, serves adults with physical disabilities between the ... include Valentine's Day treats, games and sweetheart-themed karaoke. , For more ...
(Date:1/22/2015)... its top dressmaking technologies, has been a leading dress supplier ... latest designs of wedding dresses and launching a site-wide promotion ... the fresh new products are designed for 2015, and they ... All the clothes from LunaDress follow up with the latest ...
(Date:1/22/2015)... January 22, 2015 Gabe’s Chemo Duck Program is ... the first app ever created for kids with cancer. The Chemo ... and devices, is filled with enjoyable games to help children of ... The free app helps to keep kids entertained, educated and at ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together ... by up to 30lbs in less than 12 weeks without ... Stevenson, prompting an investigative review. , “Our Incredible Bulk ... formula that allows the body to pack on a massive ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has ... View website of AngelWeddingDress.com to find more ... dresses online for a bridal party. AngelWeddingDress offers a ... them. Its maternity wedding dresses are specially designed for ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2
... Reporter , TUESDAY, July 20 (HealthDay News) -- The ... chemotherapy, is safe and can effectively treat an advanced ... researchers report. Previously it had been thought that ... life-threatening bleeding, for patients with non-squamous non-small-cell lung tumors. ...
... New Haven, onn. - A team of Yale researchers have identified ... ovarian cancer, a hard to detect and often deadly form of ... journal Cancer Research, the team showed that a variant ... ovarian cancer patients. In addition, this variant was found in 61 ...
... Those ubiquitous wires connecting listeners to you-name-the-sounds from invisible ... more likely today, Lady Gaga -- only hint at ... Now a data-driven review by Northwestern University researchers ... Reviews Neuroscience pulls together converging research from the ...
... the Law Center and Graduate College of Social Work ... Student of the Year by the National Association of Social ... 9 at the organization,s annual conference at the Westin Galleria ... graduate or undergraduate student enrolled in a social work program ...
... COLUMBIA, Mo. ... illicit drug use among all ethnic groups. Although previous ... factors can reduce their risk for substance abuse, this ... findings from a University of Missouri study reveal that ...
... Conference in Vienna are charging developed and developing country ... of people in need of lifesaving HIV treatment. ... the International Treatment Preparedness Coalition,s (ITPC), latest report, Rationing ... pullback on AIDS commitment and funding: caps on the ...
Cached Medicine News:Health News:Avastin Largely Safe for Patients With Type of Advanced Lung Cancer 2Health News:Avastin Largely Safe for Patients With Type of Advanced Lung Cancer 3Health News:Avastin Largely Safe for Patients With Type of Advanced Lung Cancer 4Health News:Yale scientists discover new genetic marker of ovarian cancer risk 2Health News:Taking music seriously 2Health News:Taking music seriously 3Health News:University of Houston's Meghan Baker named Social Work Student of the Year in Texas 2Health News:Healthy families, religious involvement buffer youth against risk factors related to drug abuse 2Health News:Writing checks that bounce: World continues to backtrack on HIV treatment 2Health News:Writing checks that bounce: World continues to backtrack on HIV treatment 3Health News:Writing checks that bounce: World continues to backtrack on HIV treatment 4Health News:Writing checks that bounce: World continues to backtrack on HIV treatment 5
... A particular challenge in transseptal left heart ... must be exchanged for a sheath with ... wall position. Traditionally, such an exchange has ... heparinized patient. Biosense Webster has overcome this ...
... of guiding introducers includes Swartz™ Series, ... piece steerable, all designed for the ... varying curves and longer sheath lengths ... Jude Medical guiding introducers are designed ...
Novus 30001 A fully-integrated and powerful 532 nm Operating Room Photocoagulator with reliable DPSS technology and simplified operation using a touch screen interface and remote control....
... 1064 nm Nd:YAG Base Platform ... ophthalmologists treating the anterior segment ... the elimination of secondary cataracts ... Selecta platform offers multiple upgrade ...
Medicine Products: